Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyadenylate-binding protein 1-like 2A (PABPC1L2A) is a member of the poly(A)-binding protein (PABP) family and is closely related, in sequence, to the canonical cytoplasmic poly(A)-binding protein PABPC1[3][5]. PABPC1L2A is distinguished by its restricted expression profile, being highly enriched in neural tissues (brain) and virtually absent from most other somatic tissues[1]. Structurally, it contains only two RNA recognition motifs (RRMs), compared to four in PABPC1, and notably lacks the C-terminal MLLE (PABC) domain—this domain in other PABPs is important for interactions with translational regulators and mRNA decay factors[3][1]. As a result, PABPC1L2A may not be functionally equivalent to universal cytoplasmic PABPs, and evidence suggests that, unlike PABPC1, it does not interact with the key translation factor eIF4G and may therefore not support general mRNA translation. Instead, it appears to be involved in neural maturation, localizing to neuronal soma and postsynaptic regions, where its main function may be the selective binding and translational repression of specific classes of neural mRNAs and long noncoding RNAs[1]. Its precise physiological role is not fully understood and PABPC1L2A is not currently established as a therapeutic target, nor are there clinically relevant drugs or biomarkers described for it. The human PABPC1L2A gene may be annotated as a putative pseudogene in some species, but conserved peptide sequences and detectable protein products in neural tissues argue for a regulated, protein-coding role in mammals[1][3][5]. Key points: - **Not established as a therapeutic target** - **Neural-specific expression in mammals** - **Likely functions in neuronal mRNA regulation and translational repression** - **Lacks important domains for canonical PABPC1 function (e.g., MLLE domain), reducing its ability to regulate translation and mRNA decay like PABPC1**
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyadenylate-binding protein 1-like 2A (PABPC1L2A).